<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="33719">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02667639</url>
  </required_header>
  <id_info>
    <org_study_id>RPH104FIH01</org_study_id>
    <nct_id>NCT02667639</nct_id>
  </id_info>
  <brief_title>First in Human Study for RPH-104</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled, Single-center, Phase I, Single-dose (4, 20, 80, 160 and 320 mg) Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RPH-104 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>TRPHARM</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>MonitorCRO</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>TRPHARM</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this fist in human study is to evaluate the safety and tolerability of
      RPH-104 in humans.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Anticipated">June 2016</completion_date>
  <primary_completion_date type="Anticipated">June 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Double Blind (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Nature, frequency, severity and relationship to study drug of recorded adverse events</measure>
    <time_frame>Until 30 days after administration</time_frame>
    <description>Assessment will be in accordance with current MedDRA</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Heart rate</measure>
    <time_frame>Until 30 days after administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Respiratory rate</measure>
    <time_frame>Until 30 days after administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Blood pressure</measure>
    <time_frame>Until 30 days after administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Oxygen saturation</measure>
    <time_frame>Until 30 days after administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Body temperature</measure>
    <time_frame>Until 30 days after administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical laboratory tests</measure>
    <time_frame>Until 30 days after administration</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>RPH-104 - Maximum plasma concentration (Cmax)</measure>
    <time_frame>Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>RPH-104 - Area Under the Curve (AUC)</measure>
    <time_frame>Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>RPH-104 - Time to maximum concentration (Tmax)</measure>
    <time_frame>Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>RPH-104 - Elimination half-life (t1/2)</measure>
    <time_frame>Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Levels of C-reactive protein (CRP)</measure>
    <time_frame>Until 30 days after administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Levels of serum amyloid A (SAA)</measure>
    <time_frame>Until 30 days after administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Levels of S100 calcium binding protein A8 (S100A8)</measure>
    <time_frame>Until 30 days after administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Interleukin-6 (IL-6) levels</measure>
    <time_frame>One month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Interleukin-1alpha (IL-1a) levels</measure>
    <time_frame>Until 30 days after administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Interleukin-1beta (IL-1B) levels</measure>
    <time_frame>Until 30 days after administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Interleukin-1 receptor antagonist (IL-1RA) levels</measure>
    <time_frame>Until 30 days after administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-RPH-104 antibody levels</measure>
    <time_frame>Until 30 days after administration</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">35</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>A single dose of RPH-104 (4, 20, 80, 160 or 320 mg) will be administered subcutaneously.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>A single 0.9% sodium chloride injection will be administered subcutaneously.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>RPH-104</intervention_name>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Sodium chloride Sterile Injection 0.9% w/v</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy subjects.

          -  Male or female subjects between 18 and 35 years old (inclusive).

          -  Subject who has normal body weight as determined by a body mass index (BMI) of
             between 18 kg/m² and 28 kg/m² (inclusive) and within a body weight of ≥50kg and
             ≤120kg.

        Exclusion Criteria:

          -  Subjects with a history or presence of cardiovascular, respiratory, hepatic, renal,
             gastrointestinal, endocrinological, dermatological, neurological, psychiatric, and
             hematological or immunological disorders

          -  Positive immunoglobulin-M (IgM) antibodies against Epstein Barr virus-viral capsid
             antigen (IgM-anti-EBV-VCA) and Cytomegalovirus (CMV).

          -  Positive Quantiferon TB-Gold (TB) test.

          -  Positive to Human Immunodeficiency Virus-1/2 antibody (HIV-1/2Ab).

          -  Positive Hepatitis B surface antigen (HBsAg), or is Hepatitis C virus antibody
             (HCV-Ab).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sibel Goksel, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>ARGEFAR</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sibel Goksel</last_name>
    <phone>+90 232 390 2286</phone>
    <email>sibel.goksel@ege.edu.tr</email>
  </overall_contact>
  <location>
    <facility>
      <name>ARGEFAR</name>
      <address>
        <city>Izmir</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <lastchanged_date>February 2, 2016</lastchanged_date>
  <firstreceived_date>January 20, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>safety</keyword>
  <keyword>tolerability</keyword>
  <keyword>RPH-104</keyword>
  <keyword>RPH104</keyword>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
